Solvonis Therapeutics PLC
06 October 2026
Solvonis Therapeutics plc
(“Solvonis” or the “Company”)
Investor Webinar – 15 October 2026
Building a leader in addiction and mental health therapeutics
LONDON – 06 October 2026 - Solvonis Therapeutics plc (LSE: SVNS), a late clinical-stage biopharmaceutical company developing small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, Solvonis Therapeutics plc (“Solvonis” or the “Company”), a late clinical-stage biopharmaceutical company developing small-molecule therapeutics for high-burden central nervous system disorders, is pleased to announce an investor webinar featuring Anthony Tennyson, Chief Executive Officer, and Professor David Nutt, Chief Scientific Officer, to be broadcast at 6:00pm BST on Thursday, 15 October 2026.
The webinar comes amid growing interest in new approaches to mental health treatment, highlighted by recent BBC coverage exploring whether psychedelic therapies could become part of mainstream NHS care:
Could psychedelic therapy become NHS treatment for mental health?
Against this backdrop, Solvonis will discuss its strategy for translating advances in neuropsychopharmacology into potential treatments for addiction and psychiatric disorders. The Company combines the repurposing of established medicines for nearer-term clinical value with proprietary drug discovery for longer-term growth.
The webinar will cover:
- Building an international alcohol use disorder franchise: SVN-001’s ongoing UK Phase 3 programme, recently announced Phase 2 analyses and planned European expansion, alongside SVN-002’s development for the US market.
- Developing proprietary medicines: SVN-015 for stimulant use disorder, supported by NIDA-funded evaluation, and SVN-114 for post-traumatic stress disorder.
- Delivering the strategy: the clinical, regulatory and commercial milestones underpinning Solvonis’ ambition to become a leader in addiction and mental health therapeutics.
Hosted by Turner Pope Investments and chaired by analyst Barry Gibb, the recorded webinar is open to shareholders and other interested investors. It will include a Q&A addressing questions submitted in advance through the registration process.
To register and submit questions, please visit:
https://www.turnerpope.com/register-svns/
Enquiries
Solvonis Therapeutics plc
Anthony Tennyson, CEO & Executive Director
info@solvonis.com
Turner Pope Investments (TPI) Limited
Corporate Broker
Andrew Thacker / Guy McDougall
+44 (0)20 3657 0050
About Solvonis Therapeutics plc
Solvonis Therapeutics plc (LSE: SVNS) is a late clinical-stage biopharmaceutical company developing small-molecule therapeutics for high-burden central nervous system (“CNS”) disorders. Headquartered in London and listed on the Main Market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and discovery-stage compounds across addiction and psychiatry.
The Company’s lead programmes target Alcohol Use Disorder (“AUD”) and Post-Traumatic Stress Disorder (“PTSD”), with additional development and discovery work supporting expansion into further addiction and psychiatric indications, including stimulant use disorder and depressive disorders.
Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in the UK, while SVN-002 is being advanced towards a planned Phase 2b trial in the United States targeting moderate-to-severe AUD. The Company’s PTSD discovery programme has identified SVN-114 as a lead compound, emerging from a proprietary compound series designed to modulate key brain-signalling systems associated with emotional processing and social behaviour.
SVN-015 is the Company’s proprietary discovery-stage candidate targeting stimulant use disorder. Following encouraging initial cardiac ion-channel and broader off-target screening results, it is advancing into further preclinical evaluation under NIDA’s Addiction Treatment Discovery Program.
In parallel, Solvonis is advancing proprietary CNS discovery programmes supported by a dedicated compound library and AI-enabled discovery capabilities to identify new small-molecule modulators of key neurotransmitter systems.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.